$3,190,000 of GILEAD SCIENCES INC lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations. Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding. Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals. Legislative and regulatory proposals to change international and domestic corporate tax law and policy."
You can find more data on corporate lobbying on Quiver Quantitative.
GILD Congressional Stock Trading
Members of Congress have traded $GILD stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 01/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
GILD Insider Trading Activity
GILD insiders have traded $GILD stock on the open market 35 times in the past 6 months. Of those trades, 0 have been purchases and 35 have been sales.
Here’s a breakdown of recent trading of $GILD stock by insiders over the last 6 months:
- DANIEL PATRICK O'DAY (Chairman & CEO) has made 0 purchases and 13 sales selling 291,280 shares for an estimated $40,879,973.
- JOHANNA MERCIER (Chief Comm & Corp Aff Officer) has made 0 purchases and 9 sales selling 68,000 shares for an estimated $9,442,901.
- DEBORAH H TELMAN (EVP, Corporate Affairs & GC) has made 0 purchases and 3 sales selling 53,646 shares for an estimated $6,590,487.
- ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 6 sales selling 17,500 shares for an estimated $2,370,865.
- JEFFREY BLUESTONE has made 0 purchases and 2 sales selling 10,000 shares for an estimated $1,242,900.
- KELLY A. KRAMER has made 0 purchases and 2 sales selling 5,611 shares for an estimated $713,186.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
GILD Hedge Fund Activity
We have seen 1,083 institutional investors add shares of GILD stock to their portfolio, and 879 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 38,953,246 shares (-75.0%) from their portfolio in Q4 2025, for an estimated $4,781,121,414
- WELLINGTON MANAGEMENT GROUP LLP removed 9,711,230 shares (-37.9%) from their portfolio in Q4 2025, for an estimated $1,191,956,370
- BLACKROCK, INC. added 6,914,187 shares (+5.9%) to their portfolio in Q4 2025, for an estimated $848,647,312
- FMR LLC added 5,263,211 shares (+8.7%) to their portfolio in Q4 2025, for an estimated $646,006,518
- CAPITAL RESEARCH GLOBAL INVESTORS removed 4,706,975 shares (-15.7%) from their portfolio in Q4 2025, for an estimated $577,734,111
- BOSTON PARTNERS added 4,220,501 shares (+inf%) to their portfolio in Q4 2025, for an estimated $518,024,292
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 4,113,999 shares (+3763.8%) to their portfolio in Q4 2025, for an estimated $504,952,237
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
GILD Analyst Ratings
Wall Street analysts have issued reports on $GILD in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 02/11/2026
- Wells Fargo issued a "Overweight" rating on 12/10/2025
- Truist Securities issued a "Buy" rating on 11/24/2025
- Scotiabank issued a "Sector Outperform" rating on 11/13/2025
- JP Morgan issued a "Overweight" rating on 10/31/2025
- TD Cowen issued a "Buy" rating on 10/23/2025
To track analyst ratings and price targets for GILD, check out Quiver Quantitative's $GILD forecast page.
GILD Price Targets
Multiple analysts have issued price targets for $GILD recently. We have seen 14 analysts offer price targets for $GILD in the last 6 months, with a median target of $155.0.
Here are some recent targets:
- Geoff Meacham from Citigroup set a target price of $165.0 on 04/13/2026
- Matthew Harrison from Morgan Stanley set a target price of $175.0 on 04/10/2026
- Akash Tewari from Jefferies set a target price of $180.0 on 03/10/2026
- Joseph Stringer from Needham set a target price of $170.0 on 02/23/2026
- Emily Field from Barclays set a target price of $155.0 on 02/20/2026
- Carter Gould from Cantor Fitzgerald set a target price of $155.0 on 02/11/2026
- Louis Chen from Scotiabank set a target price of $177.0 on 02/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
